Skip to main
COGT
COGT logo

Cogint (COGT) Stock Forecast & Price Target

Cogint (COGT) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences Inc. is positioned for significant growth due to its focus on developing CGT9486, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation responsible for systemic mastocytosis. Positive data emerging from multiple clinical trials, such as APEX, PEAK, and SUMMIT, strengthens the potential of bezuclastinib in treating various malignancies, indicating a robust pipeline for future revenue generation. The year 2025 is anticipated to be pivotal for Cogent, possibly increasing its attractiveness as a merger and acquisition target within the biotechnology sector.

Bears say

Cogent Biosciences Inc. is projected to incur a full-year net loss of $2.28 per share in 2025, indicating potential financial distress for the company. This negative outlook is compounded by significant risks, including the possibility of negative clinical data from key drug candidates, slower development timelines, and potential failures in obtaining necessary regulatory approvals. There is also concern regarding long-term dilution risks and lower-than-expected commercial success, which could further undermine investor confidence and financial performance.

Cogint (COGT) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogint (COGT) Forecast

Analysts have given Cogint (COGT) a Buy based on their latest research and market trends.

According to 11 analysts, Cogint (COGT) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogint (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.